Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Peak expiratory flow as an endpoint for clinical trials in asthma: a comparison with FEV1.

Halpin DMG, Meltzer EO, Pisternick-Ruf W, Moroni-Zentgraf P, Engel M, Zaremba-Pechmann L, Casale T, FitzGerald JM.

Respir Res. 2019 Jul 18;20(1):159. doi: 10.1186/s12931-019-1119-6.

2.

Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial.

Pascoe S, Barnes N, Brusselle G, Compton C, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Hartley B, Lange P, Lettis S, Lipson DA, Lomas DA, Martinez FJ, Papi A, Roche N, van der Valk RJP, Wise R, Singh D.

Lancet Respir Med. 2019 Jul 4. pii: S2213-2600(19)30190-0. doi: 10.1016/S2213-2600(19)30190-0. [Epub ahead of print]

PMID:
31281061
3.

It is time for the world to take COPD seriously: a statement from the GOLD board of directors.

Halpin DMG, Celli BR, Criner GJ, Frith P, López Varela MV, Salvi S, Vogelmeier CF, Chen R, Mortimer K, Montes de Oca M, Aisanov Z, Obaseki D, Decker R, Agusti A.

Eur Respir J. 2019 Jul 4;54(1). pii: 1900914. doi: 10.1183/13993003.00914-2019. Print 2019 Jul. No abstract available.

PMID:
31273036
4.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019.

Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Criner GJ, Frith P, Halpin DMG, Han M, López Varela MV, Martinez F, Montes de Oca M, Papi A, Pavord ID, Roche N, Sin DD, Stockley R, Vestbo J, Wedzicha JA, Vogelmeier C.

Eur Respir J. 2019 May 18;53(5). pii: 1900164. doi: 10.1183/13993003.00164-2019. Print 2019 May. Review.

PMID:
30846476
5.

Chronic Obstructive Pulmonary Disease Biomarkers and Their Interpretation.

Stockley RA, Halpin DMG, Celli BR, Singh D.

Am J Respir Crit Care Med. 2019 May 15;199(10):1195-1204. doi: 10.1164/rccm.201810-1860SO.

PMID:
30592902
6.

Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee.

Criner GJ, Martinez FJ, Aaron S, Agusti A, Anzueto A, Bafadhel M, Barnes PJ, Bourbeau J, Chen R, Ewig J, Fabbri LM, Frith P, Halpin DMG, Han M, Montes de Oca M, Nishimura M, O'Donnell D, Papi A, Pavord I, Roche N, Rodriguez-Roisin R, Salvi S, Singh D, Sin DD, Stockley R, López Varela MV, Vestbo J, Vogelmeier CF, Washko G, Wedzicha JA, Celli BR.

Ann Am Thorac Soc. 2019 Jan;16(1):29-39. doi: 10.1513/AnnalsATS.201808-557PS. No abstract available.

PMID:
30427736
7.

Inhalation Devices.

Moroni-Zentgraf P, Usmani OS, Halpin DMG.

Can Respir J. 2018 Sep 18;2018:5642074. doi: 10.1155/2018/5642074. eCollection 2018. No abstract available.

8.

Understanding irrationality: the key to changing behaviours and improving management of respiratory diseases?

Halpin DMG.

Lancet Respir Med. 2018 Oct;6(10):737-739. doi: 10.1016/S2213-2600(18)30364-3. Epub 2018 Sep 26. No abstract available.

PMID:
30303088
9.

Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial.

Tashkin DP, Miravitlles M, Celli BR, Metzdorf N, Mueller A, Halpin DMG, Anzueto A.

Respir Res. 2018 Oct 5;19(1):196. doi: 10.1186/s12931-018-0874-0.

10.

Palliative Care for Chronic Obstructive Pulmonary Disease. Signs of Progress, but Still a Long Way to Go.

Halpin DMG.

Am J Respir Crit Care Med. 2018 Dec 1;198(11):1356-1358. doi: 10.1164/rccm.201805-0955ED. No abstract available.

PMID:
29889550
11.

Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses.

Halpin DMG, Birk R, Brealey N, Criner GJ, Dransfield MT, Hilton E, Lomas DA, Zhu CQ, Lipson DA.

ERJ Open Res. 2018 May 4;4(2). pii: 00119-2017. doi: 10.1183/23120541.00119-2017. eCollection 2018 Apr.

12.

Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.

Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, Singh D, Tabberer M, Wise RA, Pascoe SJ; IMPACT Investigators.

N Engl J Med. 2018 May 3;378(18):1671-1680. doi: 10.1056/NEJMoa1713901. Epub 2018 Apr 18.

13.

Palliative care for people with COPD: effective but underused.

Halpin DMG.

Eur Respir J. 2018 Feb 14;51(2). pii: 1702645. doi: 10.1183/13993003.02645-2017. Print 2018 Feb. No abstract available.

14.

The Role of Tiotropium+Olodaterol Dual Bronchodilator Therapy in the Management of Chronic Obstructive Pulmonary Disease.

Halpin DMG.

Tuberc Respir Dis (Seoul). 2018 Jan;81(1):13-18. doi: 10.4046/trd.2017.0098. Review.

15.

Impact and prevention of severe exacerbations of COPD: a review of the evidence.

Halpin DM, Miravitlles M, Metzdorf N, Celli B.

Int J Chron Obstruct Pulmon Dis. 2017 Oct 5;12:2891-2908. doi: 10.2147/COPD.S139470. eCollection 2017. Review.

16.

When is dual bronchodilation indicated in COPD?

Thomas M, Halpin DM, Miravitlles M.

Int J Chron Obstruct Pulmon Dis. 2017 Aug 3;12:2291-2305. doi: 10.2147/COPD.S138554. eCollection 2017. Review.

17.

Erratum to "Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary" [Arch Bronconeumol. 2017;53:128-49].

Vogelmeier CF, Criner GJ, Martínez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DMG, Varela MVL, Nishimura M, Roche N, Rodríguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agustí A.

Arch Bronconeumol. 2017 Jul;53(7):411-412. doi: 10.1016/j.arbres.2017.06.001. English, Spanish. No abstract available.

18.

Effect of a single exacerbation on decline in lung function in COPD.

Halpin DMG, Decramer M, Celli BR, Mueller A, Metzdorf N, Tashkin DP.

Respir Med. 2017 Jul;128:85-91. doi: 10.1016/j.rmed.2017.04.013. Epub 2017 Apr 24.

19.

Why choose tiotropium for my patient? A comprehensive review of actions and outcomes versus other bronchodilators.

Halpin DM, Kaplan AG, Russell RK.

Respir Med. 2017 Jul;128:28-41. doi: 10.1016/j.rmed.2017.04.008. Epub 2017 Apr 18. Review.

20.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.

Vogelmeier CF, Criner GJ, Martínez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, López Varela MV, Nishimura M, Roche N, Rodríguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agustí A.

Arch Bronconeumol. 2017 Mar;53(3):128-149. doi: 10.1016/j.arbres.2017.02.001. Epub 2017 Mar 6. English, Spanish. Erratum in: Arch Bronconeumol. 2017 Jul;53(7):411-412.

21.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.

Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, López Varela MV, Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agusti A.

Eur Respir J. 2017 Mar 6;49(3). pii: 1700214. doi: 10.1183/13993003.00214-2017. Print 2017 Mar. Erratum in: Eur Respir J. 2017 Jun 22;49(6):.

22.

Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.

Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, López Varela MV, Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agusti A.

Respirology. 2017 Apr;22(3):575-601. doi: 10.1111/resp.13012. Epub 2017 Mar 7.

23.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary.

Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, López Varela MV, Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agustí A.

Am J Respir Crit Care Med. 2017 Mar 1;195(5):557-582. doi: 10.1164/rccm.201701-0218PP.

24.

Preference for different relaxation techniques by COPD patients: comparison between six techniques.

Hyland ME, Halpin DM, Blake S, Seamark C, Pinnuck M, Ward D, Whalley B, Greaves CJ, Hawkins AL, Seamark D.

Int J Chron Obstruct Pulmon Dis. 2016 Sep 19;11:2315-2319. eCollection 2016.

25.

Tiotropium in asthma: what is the evidence and how does it fit in?

Halpin DM.

World Allergy Organ J. 2016 Sep 14;9(1):29. doi: 10.1186/s40413-016-0119-y. eCollection 2016. Review.

26.

Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy.

Halpin DM, Kerkhof M, Soriano JB, Mikkelsen H, Price DB.

Respir Res. 2016 Sep 23;17(1):120.

27.

Effect of tiotropium on COPD exacerbations: A systematic review.

Halpin DM, Vogelmeier C, Pieper MP, Metzdorf N, Richard F, Anzueto A.

Respir Med. 2016 May;114:1-8. doi: 10.1016/j.rmed.2016.02.012. Epub 2016 Mar 2. Review.

28.

Diagnosis, assessment, and phenotyping of COPD: beyond FEV₁.

Lange P, Halpin DM, O'Donnell DE, MacNee W.

Int J Chron Obstruct Pulmon Dis. 2016 Feb 19;11 Spec Iss:3-12. doi: 10.2147/COPD.S85976. eCollection 2016. Review.

29.

The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial.

Paggiaro P, Halpin DM, Buhl R, Engel M, Zubek VB, Blahova Z, Moroni-Zentgraf P, Pizzichini E.

J Allergy Clin Immunol Pract. 2016 Jan-Feb;4(1):104-13.e2. doi: 10.1016/j.jaip.2015.08.017. Epub 2015 Nov 7.

30.

Effect of Tiotropium on Outcomes in Patients With COPD, Categorized Using the New GOLD Grading System: Results of the UPLIFT® Randomized Controlled Trial.

Halpin DMG, Tashkin DP, Celli BR, Leimer I, Metzdorf N, Decramer M.

Chronic Obstr Pulm Dis. 2015 Jun 23;2(3):236-251. doi: 10.15326/jcopdf.2.3.2014.0142.

31.

Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.

Halpin DM, Dahl R, Hallmann C, Mueller A, Tashkin D.

Int J Chron Obstruct Pulmon Dis. 2015 Feb 5;10:239-59. doi: 10.2147/COPD.S75146. eCollection 2015.

32.

Investigating Women's Experiences of Asthma Care in Pregnancy: A Qualitative Study.

Chamberlain C, Williamson GR, Knight B, Daly M, Halpin DM.

Open Nurs J. 2014 Dec 11;8:56-63. doi: 10.2174/1874434601408010056. eCollection 2014.

33.

The WISDOM of inhaled corticosteroids in COPD.

Halpin DM, Quint JK.

Thorax. 2014 Dec;69(12):1071-2. doi: 10.1136/thoraxjnl-2014-206333. Epub 2014 Oct 16. No abstract available.

34.

Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort.

Jones RC, Price D, Ryan D, Sims EJ, von Ziegenweidt J, Mascarenhas L, Burden A, Halpin DM, Winter R, Hill S, Kearney M, Holton K, Moger A, Freeman D, Chisholm A, Bateman ED; Respiratory Effectiveness Group.

Lancet Respir Med. 2014 Apr;2(4):267-76. doi: 10.1016/S2213-2600(14)70008-6. Epub 2014 Feb 13.

35.

Exacerbation frequency and course of COPD.

Halpin DM, Decramer M, Celli B, Kesten S, Liu D, Tashkin DP.

Int J Chron Obstruct Pulmon Dis. 2012;7:653-61. doi: 10.2147/COPD.S34186. Epub 2012 Sep 21.

36.

Frequency of non-asthma GP visits predicts asthma exacerbations: an observational study in general practice.

Hyland ME, Whalley B, Halpin DM, Greaves CJ, Seamark C, Blake S, Pinnuck M, Ward D, Hawkins A, Seamark D.

Prim Care Respir J. 2012 Dec;21(4):405-11. doi: 10.4104/pcrj.2012.00061.

37.

A randomised controlled trial of the effect of automated interactive calling combined with a health risk forecast on frequency and severity of exacerbations of COPD assessed clinically and using EXACT PRO.

Halpin DM, Laing-Morton T, Spedding S, Levy ML, Coyle P, Lewis J, Newbold P, Marno P.

Prim Care Respir J. 2011 Sep;20(3):324-31, 2 p following 331. doi: 10.4104/pcrj.2011.00057.

38.

Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT® trial.

Halpin DM, Decramer M, Celli B, Kesten S, Leimer I, Tashkin DP.

Lung. 2011 Aug;189(4):261-8. doi: 10.1007/s00408-011-9301-8. Epub 2011 Jun 16.

39.

Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials.

Halpin DM, Gray J, Edwards SJ, Morais J, Singh D.

Int J Clin Pract. 2011 Jul;65(7):764-74. doi: 10.1111/j.1742-1241.2011.02685.x. Review.

PMID:
21676119
40.

Improving the management of COPD.

Halpin DM.

BMJ. 2011 Apr 5;342:d1674. doi: 10.1136/bmj.d1674. No abstract available.

PMID:
21467103
41.

Preventing chronic obstructive pulmonary disease.

Halpin DM.

Expert Rev Respir Med. 2009 Oct;3(5):449-52. doi: 10.1586/ers.09.40. No abstract available.

PMID:
20477334
42.

Lessons from the major studies in COPD: problems and pitfalls in translating research evidence into practice.

Halpin DM.

Prim Care Respir J. 2010 Jun;19(2):170-9. doi: 10.4104/pcrj.2010.00015.

43.

Defining disease modification in chronic obstructive pulmonary disease.

Halpin DM, Tashkin DP.

COPD. 2009 Jun;6(3):211-25. Review.

44.

Stratification of COPD patients by previous admission for targeting of preventative care.

Bryden C, Bird W, Titley HA, Halpin DM, Levy ML.

Respir Med. 2009 Apr;103(4):558-65. doi: 10.1016/j.rmed.2008.10.027. Epub 2009 Jan 10.

45.

Uplifting times for COPD.

Halpin DM.

Prim Care Respir J. 2008 Dec;17(4):197-8. doi: 10.3132/pcrj.2008.00068. No abstract available.

46.

Guidelines versus practice: UK asthma nurses often recommend intermittent, symptom-driven use of inhaled corticosteroids.

Hyland ME, Blake S, Greaves CJ, Pinnuck M, Seamark C, Seamark D, Ward D, Halpin DM.

Prim Care Respir J. 2009 Jun;18(2):114-7. doi: 10.3132/pcrj.2008.00066.

47.

Identifying COPD patients at increased risk of mortality: predictive value of clinical study baseline data.

Halpin DM, Peterson S, Larsson TP, Calverley PM.

Respir Med. 2008 Nov;102(11):1615-24. doi: 10.1016/j.rmed.2008.05.007. Epub 2008 Aug 8.

48.

End-of-life care for patients with COPD in the community setting.

Halpin DM, Seamark CJ, Seamark DA.

Br J Gen Pract. 2008 Jun;58(551):390-2. doi: 10.3399/bjgp08X299326. No abstract available.

49.

Community care for COPD: the good, the bad and the ugly.

Halpin DM.

Thorax. 2008 Mar;63(3):187-9. doi: 10.1136/thx.2007.087783. No abstract available.

PMID:
18308953
50.

Symbicort: a pharmacoeconomic review.

Halpin DM.

J Med Econ. 2008;11(2):345-62. doi: 10.3111/13696990802210984. Review.

PMID:
19450091

Supplemental Content

Loading ...
Support Center